BioVie Targets Parkinson’s & Long COVID – DNA Age Reversal & Inflammation Insights
For biotech investors and neurology researchers: BioVie CEO Cuong Do shares promising updates on two ongoing Phase 2 trials using Bascistirum—a novel compound targeting Parkinson’s disease and long COVID. Preliminary results show reversal in biological age and gene modulation that may reduce inflammation and Alzheimer’s-related pathology.
Joining the interview is Ugochi Owo, CEO of Flindel and a member of BioVie’s Corporate Advisory Board, who emphasizes the mission-driven culture, diversity of strategic expertise, and the personal impact neurological disease has had on each member.
With trials progressing and new leadership on board, BioVie is poised for major biotech impact with top-line data expected in 2026.
💊 Ticker: BIVI
🌐 Website: bioviepharma.com
🏷️ Tags
#BioVie #BIVI #ParkinsonsResearch #LongCovidTreatment #DNAAgeReversal #Neuroinflammation #BiotechInvesting #ClinicalTrials #AgingScience #CuongDo #ugochiowo #BioViePharma #NeurodegenerativeDiseases #BiologicalClock #Phase2Trials #BiotechStocks #InflammationTreatment #AlzheimersResearch #Bascistirum #NewToTheStreet #NeuroScienceInnovation
